Phase II study of CC-486 (oral azacitidine) in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma.

•Treatment options are limited for advanced nasopharyngeal carcinoma (NPC).•Patients with advanced NPC and ≤2 prior regimens received CC-486 (oral azacitidine).•Overall response rate was 12%, and median progression-free survival was 4.7 months.•CC-486 showed insufficient activity to support further development in advanced NPC.•The safety profile of CC-486 in NPC was consistent with that in other solid tumours.